Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: Observations from PROVE IT-TIMI 22

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 1, 2011, Pages 203-210

  Bonaca, Marc P ^a   Morrow, David A ^a   Braunwald, Eugene ^a   Cannon, Christopher P ^a   Jiang, Songtao ^b   Breher, Stephanie ^c   Sabatine, Marc S ^a   Kempf, Tibor ^c   Wallentin, Lars ^d   Wollert, Kai C ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

acute coronary syndromes; cholesterol lowering drugs; coronary artery disease; cytokines; heart failure; outcomes; unstable angina

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; CARDIAC PATIENT; CONGESTIVE HEART FAILURE; DEATH; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SMOKING; TISSUE INJURY;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; EUROPE; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PATIENT DISCHARGE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 78650860293     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.213512     Document Type: Article

References (27)

1. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation. 2003; 108:250-252.
2. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 1997;94:11514-11519.
3. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/ reperfusion injury. Circ Res. 2006;98:351-360.
4. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin. 2009;5:537-547.
5. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K, Metz J, Kinscherf R. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDLinduced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004;318:325-333.
6. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet. 2002;359:2159-2163.
7. Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28:2858-2865.
8. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007;53:284-291.
9. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054-1060.
10. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, Peter T, Siegbahn A, Venge P, Drexler H, Wallentin L. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116: 1540-1548.
11. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115:962-971.
12. Eggers KM, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Jantzen F, Peter T, Allhoff T, Siegbahn A, Venge P, Wollert KC, Wallentin L. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet. 2010;3:88-96.
13. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009;30:1057-1065.
14. Pencina MJ, D'Agostino RBS, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157, 172; discussion, 207-212.
15. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949-952.
16. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
17. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
18. Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, Rifai N, Braunwald E, Morrow DA; PROVE IT-TIMI 22 Investigators. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009;55:265-273.
19. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications, part 2. Clin Chem. 2001;47:418-425.
20. Wu AH, Packer M, Smith A, Bijou R, Fink D, Mair J, Wallentin L, Johnston N, Feldcamp CS, Haverstick DM, Ahnadi CE, Grant A, Despres N, Bluestein B, Ghani F. Analytical and clinical evaluation of the bayer ADVIA centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem. 2004;50:867-873.
21. Clerk A, Kemp TJ, Zoumpoulidou G, Sugden PH. Cardiac myocyte gene expression profiling during H2O2-induced apoptosis. Physiol Genomics. 2007;29:118-127.
22. Frank D, Kuhn C, Brors B, Hanselmann C, Ludde M, Katus HA, Frey N. Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension. 2008;51:309-318.
23. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98: 342-350.
24. Eggers KM, Kempf T, Allhoff T, Lindahl B, Wallentin L, Wollert KC. Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J. 2008;29:2327-2335.
25. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC. Growthdifferentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the prospective investigation of the vasculature in uppsala seniors (PIVUS) study. Eur Heart J. 2009;30:2346-2353.
26. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Am J Cardiol. 2010;106: 204-209.
27. Taddei S, Virdis A. Growth differentiation factor-15 and cardiovascular dysfunction and disease: malefactor or innocent bystander? Eur Heart J. 2010;31:1168-1171.